Form 4: Title 19 Promis Acquires Shares and Warrants in ProMIS Neurosciences Private Placement

Title 19 Promis acquired common shares and warrants in ProMIS Neurosciences through a private placement and conversion of preferred shares.

Summary

• On July 31, 2024, Title 19 Promis acquired 465,116 units in a private placement by ProMIS Neurosciences, with each unit consisting of one common share, one Tranche A warrant, one Tranche B warrant, and one Tranche C warrant.
• The purchase price for each unit was $2.15.
• Title 19 Promis also acquired 500,000 common shares through the conversion of Series 2 Preferred Shares at a 1:1 ratio.
• Following these transactions, Title 19 Promis beneficially owns 1,575,629 common shares acquired through the private placement and 2,075,629 common shares acquired through the conversion of preferred shares.
• Each tranche of warrants consists of 465,116 warrants.
• Tranche A and B warrants have an exercise price of $2.02 per share, while Tranche C warrants have an exercise price of $2.50 per share.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and warrants by Title 19 Promis suggests confidence in the company's prospects, but the contingent nature of some warrant terms introduces some uncertainty.

Positives

• Title 19 Promis increased its stake in ProMIS Neurosciences through a private placement and conversion of preferred shares.
• The investment signals confidence in ProMIS Neurosciences' prospects.

Risks

• The exercisability of Tranche A and B warrants is contingent on Nasdaq approval, which introduces uncertainty.
• The expiration of Tranche A and B warrants is tied to the announcement of clinical data, which could impact their value.

Future Outlook

The document does not contain explicit forward-looking statements beyond the warrant expiration terms tied to clinical data announcements.

Industry Context

Form 4 filings are standard disclosures for significant changes in beneficial ownership, providing transparency to the market regarding insider activity. This filing indicates investment activity by a major shareholder in a biotechnology company.

Comparison to Industry Standards

• Private placements are a common method for biotechnology companies like ProMIS Neurosciences to raise capital.
• Warrants are frequently included in such placements to incentivize investment.
• The specific terms of the warrants (exercise price, expiration date) are typical for early-stage biotech companies.

Stakeholder Impact

• Shareholders may view the increased investment by Title 19 Promis positively.
• The capital raised through the private placement can support ProMIS Neurosciences' research and development efforts.

Next Steps

• ProMIS Neurosciences needs to obtain Nasdaq approval for the issuance of shares upon exercise of Tranche A and B warrants.
• The expiration dates of Tranche A and B warrants are dependent on the announcement of clinical data from PMN310 trials.

Key Dates